Nathan J. J Alves

Prof. Nathan J. J Alves

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Environmental Pollution
Verified
Journal Article
Closed access
ZLZachary Lett
Zachary Lett
AHAbigail Hall
Abigail Hall
SSShelby Skidmore
Shelby Skidmore
NANathan J. J Alves
Nathan J. J Alves

29 October 2015 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
NANathan J. J Alves
Nathan J. J Alves
KTKendrick B. Turner
Kendrick B. Turner
MDMichael A. Daniele
Michael A. Daniele
EOEunkeu Oh
Eunkeu Oh
IMIgor L. Medintz
Igor L. Medintz
Scott A. WalperScott A. Walper
Scott A. Walper

5 March 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JHJohn A. Hondred
John A. Hondred
JBJoyce C. Breger
Joyce C. Breger
NANathan J. J Alves
Nathan J. J Alves
Scott TrammellScott Trammell
Scott Trammell
Scott A. WalperScott A. Walper
Scott A. Walper
Jonathan ClaussenJonathan Claussen
Jonathan Claussen

27 April 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NANathan J. J Alves
Nathan J. J Alves
KTKendrick B. Turner
Kendrick B. Turner
IMIgor L. Medintz
Igor L. Medintz
Scott A. WalperScott A. Walper
Scott A. Walper
Bacteria possess innate machinery to transport extracellular cargo between cells as well as package virulence factors to infect host cells by secreting outer membrane vesicles (OMVs) that contain small molecules, proteins and genetic material. These robust proteoliposomes have evolved naturally to be resistant to degradation and provide a supportive environment to extend the activity of encapsulated cargo. In this study, we sought to exploit bacterial OMV formation to package and maintain the activity of an enzyme, phosphotriesterase (PTE), under challenging storage conditions encountered for real world applications. Here we show that OMV packaged PTE maintains activity over free PTE when subjected to elevated temperatures (>100-fold more activity after 14 days at 37 °C), iterative freeze-thaw cycles (3.4-fold post four-cycles) and lyophilization (43-fold). We also demonstrate how lyophilized OMV packaged PTE can be utilized as a cell free reagent for long term environmental remediation of pesticide/chemical warfare contaminated areas.

23 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
APAbhimanyu S. Paraskar
Abhimanyu S. Paraskar
SSShivani Soni
Shivani Soni
KCKenneth T. Chin
Kenneth T. Chin
PCPadmaparna Chaudhuri
Padmaparna Chaudhuri
KMKatherine W. Muto
Katherine W. Muto
SSShiladitya Sengupta
Shiladitya Sengupta
Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-rasLSL/+/Ptenfl/flovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasma spectroscopy. Given the universal need for a better platinate, we anticipate this coupling of nanotechnology and structure-activity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.

20 April 2012 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
TKT Kiziltepe
T Kiziltepe
JAJ D Ashley
J D Ashley
JSJ F Stefanick
J F Stefanick
YQY M Qi
Y M Qi
NANathan J. J Alves
Nathan J. J Alves
BBB Bilgicer
B Bilgicer
In the continuing search for effective cancer treatments, we report the rational engineering of a multifunctional nanoparticle that combines traditional chemotherapy with cell targeting and anti-adhesion functionalities. Very late antigen-4 (VLA-4) mediated adhesion of multiple myeloma (MM) cells to bone marrow stroma confers MM cells with cell-adhesion-mediated drug resistance (CAM-DR). In our design, we used micellar nanoparticles as dynamic self-assembling scaffolds to present VLA-4-antagonist peptides and doxorubicin (Dox) conjugates, simultaneously, to selectively target MM cells and to overcome CAM-DR. Dox was conjugated to the nanoparticles through an acid-sensitive hydrazone bond. VLA-4-antagonist peptides were conjugated via a multifaceted synthetic procedure for generating precisely controlled number of targeting functionalities. The nanoparticles were efficiently internalized by MM cells and induced cytotoxicity. Mechanistic studies revealed that nanoparticles induced DNA double-strand breaks and apoptosis in MM cells. Importantly, multifunctional nanoparticles overcame CAM-DR, and were more efficacious than Dox when MM cells were cultured on fibronectin-coated plates. Finally, in a MM xenograft model, nanoparticles preferentially homed to MM tumors with ∼10 fold more drug accumulation and demonstrated dramatic tumor growth inhibition with a reduced overall systemic toxicity. Altogether, we demonstrate the disease driven engineering of a nanoparticle-based drug delivery system, enabling the model of an integrative approach in the treatment of MM.